Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: john jansen who wrote (678)	6/4/1999 4:48:00 PM
From: john jansen	Respond to of 705

check out trading today on NEOT????

To: john jansen who wrote (678)	6/4/1999 11:39:00 PM
From: Marty	Read Replies (2) \| Respond to of 705

Thanks for the Econ 101 lesson, but even in grade school you learn that: 1) Big institutions can't take a position in a company with so few shares outstanding. Getting more shares in the float makes NEOT eligible for institutions that may have wanted to take a position but couldn't with so few shares in the float. Even so, NEOT will still have fewer shares in the float after the secondary offering than most other comparable companies. 2) Prices are made by supply and demand. The market makers they now have would buy all the shares they could at 14 or 15 if they felt they could sell them at 14 1/4 or 15 1/4 (or more). There will be no problem with demand if the Neotrofin turns out to be the drug many suspect it is now. That is whether or not any large investment banker sponsors it. I grant you that it would be nice to have a large brokerage house sales force recommending it. Even that, however, wouldn't last long if the drug doesn't work. 3) Big pharmas have agendas of their own with other drugs they may want to develop. Check out the progress on the same type of drug at Guilford. It is on the back burner for over a year since they made their pharma deal. Every pharma has contacted NEOT to make a deal already. Nobody said billion dollar companies are stupid. NEOT has absolutely no need to make a deal with one now. All they need is the marketing from the pharma and it would be better for all of us if they made that deal after the testing is successfully completed. We must have gone to different schools.